诱导多能干细胞(IPSCs)在心血管疾病研究中的应用  

Applications of Induced Pluripotent Stem Cells (IPS) in the Study of Cardiovascular Disease

作　　者：刘天龙[1] 刘晶[1] 肖宁[2] 刘小雷[3] 陈敬洲[2] 

机构地区：[1]内蒙古医科大学附属医院药剂部,呼和浩特市010010 [2]中国医学科学院北京协和医学院国家心血管中心阜外心血管病医院心血管疾病国家重点实验室,北京市100037 [3]内蒙古医科大学药理室,呼和浩特市010059

出　　处：《中国分子心脏病学杂志》2016年第6期1937-1939,共3页Molecular Cardiology of China

基　　金：国家自然科学基金项目(81460066)

摘　　要：改变终末分化细胞的可塑性使其重新具有多能性是生物医学研究在21世纪的重要突破。人诱导多能干细胞(Human-induced plu r ipotent stem cells,i PSCs)的出现不仅在一定程度上避免了胚胎干细胞在技术、伦理和免疫排斥反应上的限制,而且为基础医学研究和再生医学研究提供了新的工具。2002年,世界卫生组织统计显示,心血管疾病已经成为非感染性死亡的首要原因,并有逐年增加的趋势。由于心血管疾病研究方法上限制,如动物模型不能很好反映人的疾病状态、人源心肌样本缺少及原代心肌细胞获得和培养困难等,为该病的研究和相关疾病发病机制的阐明提供了障碍。目前研究显示,i PSCs在心肌损伤修复,心血管疾病相关模型的建立和治疗药物筛选等方面表现出一定的优势和应用前景。本文就i PSCs在心血管疾病中的应用做如下综述。Changing the plasticity of terminally differentiated cells to enable them to be pluripotent is an important breakthrough in biomedical research in the 21 st century. The emergence of human-induced pluripotent stem cells（i PSCs） not only to a certain extent to avoid the restrictions of embryonic stem cells, such in the technical, ethical and immune rejection, but also provides a new tool for basic medical and regenerative medicine research. In 2002, the World Health Organization statistics show that cardiovascular disease has become the primar y cause of non-infectious death. As a limit of cardiovascular disease research methods, such as animal models defect, the lack of human myocardial samples and primary myocardial cell from human, provide an obstacle for elucidating mechanisms of cardiovascular disease. Studies have shown that i PSCs has certainly advantages and application prospects in myocardial injury repair, establishing cardiovascular disease-related model and drug screening, which was summarized in this paper.

关 键 词：诱导多能干细胞 心血管疾病 研究进展 

分 类 号：R54[医药卫生—心血管疾病]